Valuation: ANI Pharmaceuticals, Inc.

Market Cap 1.73B 1.52B 1.42B 1.31B 2.44B 166B 2.5B 16.87B 6.6B 82.19B 6.51B 6.37B 284B P/E 2026 *
15.7x
P/E 2027 * 13.9x
Enterprise Value 1.89B 1.66B 1.55B 1.42B 2.67B 181B 2.73B 18.4B 7.2B 89.66B 7.1B 6.95B 310B EV / Sales 2026 *
1.69x
EV / Sales 2027 * 1.34x
Free-Float
86.61%
Yield 2026 *
-
Yield 2027 * -
1 day+0.91%
1 week+5.37%
Current month-1.21%
1 month-2.78%
3 months+4.89%
6 months-0.27%
Current year+3.60%
1 week 77.43
Extreme 77.43
82
1 month 76.42
Extreme 76.425
87.19
Current year 70.15
Extreme 70.15
87.76
1 year 62.6
Extreme 62.605
99.5
3 years 48.2
Extreme 48.2
99.5
5 years 22.31
Extreme 22.31
99.5
10 years 22.31
Extreme 22.31
99.5
Manager TitleAgeSince
Chief Executive Officer 48 2020-09-07
Director of Finance/CFO 55 2016-05-05
Compliance Officer - 2022-02-23
Director TitleAgeSince
Chairman 62 2025-11-23
Director/Board Member 68 2020-08-05
Director/Board Member 66 2020-08-05
Date Insider Type Main position Quantity % Market Cap.
7/18/26 Tax

General Counsel

-2,466 0.0108%
7/13/26 Sell

General Counsel

-500 0.0022%
7/2/26 Fiscal year

Chief Financial Officer

9,939 0.0437%
Change 5-day change 1-year change 3-year change Capi.($)
+0.91%+5.37%+27.38%+56.19% 1.73B
-0.87%+4.04%+58.60%+163.92% 1,079B
-0.45%+3.87%+57.95%+52.18% 640B
+0.04%+3.95%+37.69%+74.54% 465B
-1.89%+1.46%+36.59%+31.04% 353B
-1.54%+0.03%+34.39%+40.22% 301B
-2.02%+1.29%+11.78%+14.89% 271B
-1.57%+3.82%+2.32%-39.10% 228B
-1.39%+5.90%+27.70%+64.00% 209B
-1.18%+1.83%+16.20%+72.69% 165B
Average -1.07%+4.89%+31.06%+53.06% 371.14B
Weighted average by Cap. -1.17%+4.87%+41.31%+77.75%

Financials

2026 *2027 *
Net sales 1.12B 986M 920M 844M 1.58B 107B 1.62B 10.91B 4.27B 53.16B 4.21B 4.12B 184B 1.24B 1.09B 1.02B 935M 1.75B 119B 1.79B 12.07B 4.72B 58.84B 4.66B 4.56B 203B
Net income 117M 103M 96.09M 88.18M 165M 11.22B 169M 1.14B 446M 5.55B 440M 430M 19.2B 175M 154M 143M 132M 246M 16.74B 252M 1.7B 665M 8.29B 656M 642M 28.64B
Net Debt 158M 138M 129M 119M 222M 15.1B 228M 1.53B 599M 7.47B 592M 579M 25.82B -71.89M -63.17M -58.97M -54.11M -101M -6.89B -104M -699M -273M -3.41B -270M -264M -11.78B
Logo ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Employees
970
Date Price Change Volume
26-07-29 US$81.78 +0.91% 288,346
26-07-28 US$81.04 +3.41% 219,650
26-07-27 US$78.37 +0.93% 352,408
26-07-24 US$77.65 -1.12% 157,981
26-07-23 US$78.53 +1.19% 245,695
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
81.78USD
Average target price
110.00USD
Spread / Average Target
+34.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANIP Stock